Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 4.95 USD 5.1%
Market Cap: 952m USD

Wall Street
Price Targets

ABUS Price Targets Summary
Arbutus Biopharma Corp

Wall Street analysts forecast ABUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABUS is 5.78 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

Lowest
Price Target
5.05 USD
2% Upside
Average
Price Target
5.78 USD
17% Upside
Highest
Price Target
7.35 USD
48% Upside
Arbutus Biopharma Corp Competitors:
Price Targets
300685
Amoy Diagnostics Co Ltd
45% Upside
6855
Ascentage Pharma Group International
83% Upside
BCYC
Bicycle Therapeutics PLC
200% Upside
BAVA
Bavarian Nordic A/S
37% Upside
AGIO
Agios Pharmaceuticals Inc
22% Upside
SPRB
Spruce Biosciences Inc
165% Upside
OPK
OPKO Health Inc
177% Upside
251120
Bio-FD&C Co Ltd
23% Upside

Revenue
Forecast

Revenue Estimate
Arbutus Biopharma Corp

For the last 13 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -7%. The projected CAGR for the next 3 years is 13%.

-7%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Arbutus Biopharma Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Arbutus Biopharma Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABUS's stock price target?
Price Target
5.78 USD

According to Wall Street analysts, the average 1-year price target for ABUS is 5.78 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

What is Arbutus Biopharma Corp's Revenue forecast?
Projected CAGR
13%

For the last 13 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -7%. The projected CAGR for the next 3 years is 13%.

Back to Top